{"protocolSection":{"identificationModule":{"nctId":"NCT00651690","orgStudyIdInfo":{"id":"191622-065"},"organization":{"fullName":"Allergan","class":"INDUSTRY"},"briefTitle":"Study of Responsiveness of Seven Functional Tasks in Patients With Poststroke Upper Limb Spasticity With Botulinum Toxin Type A Treatment"},"statusModule":{"statusVerifiedDate":"2008-05","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2004-03"},"primaryCompletionDateStruct":{"date":"2005-05","type":"ACTUAL"},"completionDateStruct":{"date":"2005-05","type":"ACTUAL"},"studyFirstSubmitDate":"2008-04-01","studyFirstSubmitQcDate":"2008-04-02","studyFirstPostDateStruct":{"date":"2008-04-03","type":"ESTIMATED"},"lastUpdateSubmitDate":"2008-05-23","lastUpdatePostDateStruct":{"date":"2008-05-28","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"oldNameTitle":"Therapeutic Area Head","oldOrganization":"Allergan, Inc."},"leadSponsor":{"name":"Allergan","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"This study evaluates the responsiveness of 7 functional tasks to botulinum toxin Type A treatment in poststroke patients with spasticity of the upper-limb flexors"},"conditionsModule":{"conditions":["Stroke","Muscle Spasticity"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":62,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"1","type":"EXPERIMENTAL","description":"Botulinum Toxin Type A","interventionNames":["Biological: Botulinum Toxin Type A"]},{"label":"2","type":"PLACEBO_COMPARATOR","description":"Saline","interventionNames":["Biological: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"Botulinum Toxin Type A","description":"200 U to 360 U of botulinum toxin Type A on Day 0. Patients who met retreatment criteria received a second treatment (open-label) at Week 12 or Week 18","armGroupLabels":["1"],"otherNames":["BOTOXÂ®"]},{"type":"BIOLOGICAL","name":"Placebo","description":"Saline injection on Day 0","armGroupLabels":["2"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Seven functional tasks (nail filing, hand cleaning, holding a water bottle, brushing teeth, holding a small fruit, holding a medium fruit, and holding a large fruit)","timeFrame":"Week 6"}],"secondaryOutcomes":[{"measure":"Spasticity of the upper-limb flexors as measured by the Ashworth Scale","timeFrame":"Week 6"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Medically stable poststroke with focal unilateral upper-limb spasticity\n\nExclusion Criteria:\n\n* Stroke within 6 months of the study enrollment visit\n* Previous or current botulinum toxin therapy of any type in the study limb","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Director","affiliation":"Allergan","role":"STUDY_DIRECTOR"}],"locations":[{"city":"Indianapolis","state":"Indiana","country":"United States","geoPoint":{"lat":39.76838,"lon":-86.15804}}]},"referencesModule":{"references":[{"pmid":"16731213","type":"BACKGROUND","citation":"Turkel CC, Bowen B, Liu J, Brin MF. Pooled analysis of the safety of botulinum toxin type A in the treatment of poststroke spasticity. Arch Phys Med Rehabil. 2006 Jun;87(6):786-92. doi: 10.1016/j.apmr.2006.02.015."},{"type":"BACKGROUND","citation":"Turkel C, Bowen B, Liu J, Brin M. A pooled analysis of the safety of BoNTA (BOTOX(R)) in the treatment of poststroke spasticity. Neurorehabil Neural Repair 2006;20(1):200 ABS-P3-081"}],"seeAlsoLinks":[{"label":"Link to Clinical Trial Results","url":"http://www.allerganclinicaltrials.com"}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000009128","term":"Muscle Spasticity"}],"ancestors":[{"id":"D000009135","term":"Muscular Diseases"},{"id":"D000009140","term":"Musculoskeletal Diseases"},{"id":"D000009122","term":"Muscle Hypertonia"},{"id":"D000020879","term":"Neuromuscular Manifestations"},{"id":"D000009461","term":"Neurologic Manifestations"},{"id":"D000009422","term":"Nervous System Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M11775","name":"Muscle Spasticity","asFound":"Muscle Spasticity","relevance":"HIGH"},{"id":"M11782","name":"Muscular Diseases","relevance":"LOW"},{"id":"M11787","name":"Musculoskeletal Diseases","relevance":"LOW"},{"id":"M11769","name":"Muscle Hypertonia","relevance":"LOW"},{"id":"M22309","name":"Neuromuscular Manifestations","relevance":"LOW"},{"id":"M12094","name":"Neurologic Manifestations","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC05","name":"Musculoskeletal Diseases"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000001905","term":"Botulinum Toxins"},{"id":"D000019274","term":"Botulinum Toxins, Type A"},{"id":"C000542869","term":"abobotulinumtoxinA"}],"ancestors":[{"id":"D000065087","term":"Acetylcholine Release Inhibitors"},{"id":"D000049990","term":"Membrane Transport Modulators"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000018678","term":"Cholinergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000009465","term":"Neuromuscular Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"}],"browseLeaves":[{"id":"M4873","name":"Botulinum Toxins","asFound":"250","relevance":"HIGH"},{"id":"M250157","name":"abobotulinumtoxinA","asFound":"Previous","relevance":"HIGH"},{"id":"M20947","name":"Botulinum Toxins, Type A","asFound":"Previous","relevance":"HIGH"},{"id":"M3163","name":"Acetylcholine","relevance":"LOW"},{"id":"M20448","name":"Cholinergic Agents","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"VaDiAg","name":"Vasodilator Agents"}]}},"hasResults":false}